Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

TitleLocalization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.
Publication TypeJournal Article
Year of Publication2002
AuthorsShoghi-Jadid, K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang S-C, Barrio JR
JournalThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
Volume10
Issue1
Pagination24-35
Date Published2002 Jan-Feb
ISSN1064-7481
KeywordsAged, Aged, 80 and over, Alzheimer Disease, Amyloid beta-Peptides, Brain, Case-Control Studies, Female, Fluorescent Dyes, Fluorodeoxyglucose F18, Humans, Male, memory, Middle Aged, Naphthalenes, Neurofibrillary Tangles, Neuropsychological Tests, Nitriles, Plaque, Amyloid, Predictive Value of Tests, Radiopharmaceuticals, Tomography, Emission-Computed
Abstract

The authors used 2-(1-(6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene)malononitrile ([18F]FDDNP), a hydrophobic radiofluorinated derivative of 2-(1-[6-(dimethylamino)-2-naphthyl]ethylidene)malononitrile (DDNP), in conjunction with positron emission tomography to determine the localization and load of neurofibrillary tangles (NFTs) and beta-amyloid senile plaques (APs) in the brains of living Alzheimer disease (AD) patients. Previous work illustrated the in vitro binding characteristics of [18F]FDDNP to synthetic beta-amyloid(1-40) fibrils and to NFTs and APs in human AD brain specimens. In the present study, greater accumulation and slower clearance was observed in AP- and NFT-dense brain areas and correlated with lower memory performance scores. The relative residence time of the probe in brain regions affected by AD was significantly greater in patients with AD (n=9) than in control subjects (n=7; p=0.0007). This noninvasive technique for monitoring AP and NFT development is expected to facilitate diagnostic assessment of patients with AD and assist in response-monitoring during experimental treatments.

DOI10.1111/j.1528-1167.2011.03065.x
Alternate JournalAm J Geriatr Psychiatry